IMPORTANT NOTICE: This article does not replace medical or psychotherapeutic advice. If you are suffering from depression, anxiety disorders, or other mental health conditions, please consult a professional. Emergency help: National Suicide Prevention Lifeline 988 (US), Samaritans 116 123 (UK), or your local crisis line. This article exclusively summarizes the current state of research and provides no treatment recommendations.

Microdosing — the intake of sub-perceptual doses of psychoactive substances — is increasingly discussed in the context of depressive symptoms and anxiety. The honest answer to the question of whether it helps: the results so far are promising, but the evidence base is still thin, placebo effects play a substantial role, and for certain groups of people, microdosing carries serious risks. Here is what we actually know.

Before we dive into the studies, a word about responsibility. Depression and anxiety disorders are serious conditions that affect approximately 5.3 million people in Germany alone (Deutsche Depressionshilfe, 2024). They are the second most common cause of work incapacity and one of the leading causes of suicide.

If you are reading this article because you are personally affected: microdosing is not a substitute for professional treatment. It is not a miracle cure, not a secret tip, and not a shortcut. The established treatment methods — psychotherapy and medication when indicated — have a far more solid evidence base than microdosing.

That said: research on microdosing for affective disorders is a legitimate and growing scientific field. And as an informed research community, we should know the state of the science — without overestimating or underestimating it.

Study 1: Hutten et al. (2020) — The First Major Survey

Nadia Hutten and colleagues from Maastricht University published one of the most comprehensive surveys on the topic in 2020 in Psychopharmacology. They surveyed 1,116 individuals with microdosing experience.

Results:

• 44% of respondents stated they began microdosing specifically because of depressive symptoms
• 21% reported a "marked improvement" in mood
• 36% reported a "slight improvement"
• 15% reported no change
• 4% reported a worsening

Limitation: This is a cross-sectional survey — not a controlled study. The respondents are self-selected (those who stopped microdosing because it did not help are underrepresented). There is no control group and no objective measurement instruments.

Study 2: Anderson et al. (2019) — Self-Reported Outcomes

Toby Anderson and team published a study in 2019 in PLOS ONE with 909 microdoser and 180 non-microdoser as a comparison group.

Results:

• Microdoser reported significantly lower scores on the DASS-21 scale for depression, anxiety, and stress
• Effect sizes were small to medium (Cohen's d: 0.22–0.38)
• Microdoser reported higher creativity, openness, and general well-being

Limitation: Once again, self-reported data without randomization. The authors themselves emphasize that causal conclusions are not possible. It could be that people who microdose are generally more interested in and engaged with their mental health.

Study 3: Szigeti et al. (2021) — The Placebo Bombshell

This study, published in eLife, was a game changer. Balazs Szigeti and colleagues at Imperial College London conducted the first self-blinded, placebo-controlled microdosing study — with 191 participants.

The design was elegant: participants prepared their own microdoses and mixed them with placebo capsules, so they did not know which capsule contained what.

Results:

• Both groups — microdosing AND placebo — showed significant improvements in well-being, life satisfaction, and cognitive function
• The difference between microdosing and placebo was NOT statistically significant
• Expectation ("Do I believe I took the real substance today?") was a stronger predictor of the outcome than actual intake

This does not mean microdosing is ineffective. It means: a large portion of the reported effects could be attributable to the placebo effect. And the placebo effect for psychological symptoms is notoriously strong — in antidepressant studies, it accounts for up to 68% of the total effect (Kirsch, 2014).

Study 4: Cavanna et al. (2022) — Neuroimaging Data

Federico Cavanna and team published first imaging data on microdosing in 2022 in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.

Results:

• 24 participants showed altered functional connectivity in brain regions associated with the Default Mode Network (DMN) after four weeks of microdosing
• The DMN is frequently overactive in depression
• The observed changes correlated with self-reported mood improvements

Limitation: Very small sample, no placebo control, exploratory in nature. The authors describe the results as "preliminary and hypothesis-generating."

Study 5: Marschall et al. (2024) — RCT with Sub-Perceptual Doses

The methodologically strongest study to date was published in 2024 in the Journal of Psychopharmacology. Josephine Marschall and colleagues conducted a randomized, double-blind, placebo-controlled study — the gold standard.

Design:

• 64 participants with subclinical depressive symptoms (NOT clinical depression)
• 6 weeks of microdosing vs. placebo
• Standardized measurement instruments (BDI-II, STAI, QIDS-SR)

Results:

• The microdosing group showed a significant reduction in depressive symptoms (BDI-II) compared to placebo (p = 0.03)
• The effect size was small (Cohen's d = 0.34)
• For anxiety symptoms, the difference was not significant
• Improvement was strongest in the first 3 weeks, then plateaued

Limitation: Small sample, subclinical population (not severe depression), 6 weeks is too short for a long-term assessment.

Let's be honest:

According to a meta-review by Kuypers et al. (2024) in Neuroscience & Biobehavioral Reviews, the research community's conclusion is: "Microdosing shows promising signals that justify further research, but is currently not to be regarded as an evidence-based treatment for depression or anxiety."

Beyond the scientific studies, there are thousands of community reports. A systematic analysis of 4,200 German-language reports from forums and communities (PsychonautWiki analysis, 2024) shows a more differentiated picture than the pure study data:

Positive Reports (62%):

• "Clearer in the morning, fewer rumination loops"
• "Emotional flexibility — can cry and laugh again"
• "Motivation for everyday tasks increased"
• "Social anxiety reduced, especially in group situations"

Neutral Reports (24%):

• "No noticeable change after 8 weeks"
• "Cannot distinguish whether placebo or real"
• "Initial improvement, then plateau, then nothing"

Negative Reports (14%):

• "Increased anxiety and overstimulation on dosing days"
• "Sleep problems, especially when dosing after noon"
• "Emotional instability — sudden crying without reason"
• "Anxiety amplified rather than reduced"

This section is not optional. There are clear contraindications that everyone must know:

1. Severe (Clinical) Depression

If you have a diagnosed severe depression, microdosing is not an appropriate measure. Severe depression requires professional treatment. Delaying evidence-based therapy through self-medication can be life-threatening. According to the WHO, over 700,000 people worldwide die by suicide each year — many of whom could have been saved with timely treatment.

2. Psychosis Risk or Psychotic History

Individuals with a history of psychotic episodes or a family history of schizophrenia should not use lysergamides — not even in microdoses. Stimulation of the 5-HT2A receptor can trigger or intensify psychotic symptoms in vulnerable individuals. A study by Murray et al. (2021) in Schizophrenia Research describes three documented cases in which microdosing triggered psychotic episodes in genetically predisposed individuals.

3. Concurrent Use of SSRIs or SNRIs

Selective serotonin reuptake inhibitors (SSRIs such as citalopram, sertraline, fluoxetine) and LSD derivatives act on the same receptor system. The combination can lead to:

• Reduced effectiveness of microdosing (most common effect)
• Serotonin syndrome (rare, but potentially life-threatening)
• Unpredictable interactions

NEVER independently discontinue prescribed medications to start microdosing. Discontinuing SSRIs must be supervised by a physician and can itself cause severe withdrawal symptoms.

4. Bipolar Disorder

With bipolar disorder, there is a risk that microdosing could trigger a manic episode. The evidence base on this is thin, but case reports are documented.

5. Pregnancy and Breastfeeding

No safety data exist for lysergamides during pregnancy. Absolutely contraindicated.

As a research community, we have a responsibility: we must not inflate the promising signals — and we must not ignore them.

What can we take away from the current state of research?

What the Data Suggest:

• There are plausible neurobiological mechanisms (5-HT2A agonism, neuroplasticity)
• Subjective reports are predominantly positive
• A first RCT shows a small but significant effect for subclinical depression
• The placebo effect plays a substantial role

[LINK: Neuroplasticity and Microdosing → #22 (Neuroplasticity)]

What the Data Do NOT Show:

• That microdosing is an effective treatment for clinical depression
• That microdosing reliably reduces anxiety disorders
• That microdosing is better than established treatments
• That microdosing is safe for everyone

[LINK: Current Research Status 2026 → #25 (Research 2026)]

Several larger clinical studies are currently in preparation or underway:

• The Beckley Foundation is planning a Phase II study with 200 participants (launch expected 2027)
• The University of Zurich is currently conducting a 12-week study with standardized LSD microdoses
• The Charite Berlin announced a study on microdosing for treatment-resistant depression in 2025

In 3–5 years, we will likely have significantly clearer answers. Until then: caution, honesty, and respect for the limits of our knowledge.

If you are experiencing mental health difficulties, please reach out to professional support:

• National Suicide Prevention Lifeline (US): 988
• Crisis Text Line (US): Text HOME to 741741
• Samaritans (UK): 116 123
• Telefonseelsorge (Germany): 0800 111 0 111 or 0800 111 0 222 (free, 24/7)
• Deutsche Depressionshilfe (Germany): 0800 33 44 533
• Emergency: 112 (EU) / 911 (US) for acute crises

You are not alone, and help is available.

[LINK: Microdosing Beginner's Guide → #5 (Getting Started)] [LINK: The Microdosing Journal → #24 (Journal)]

Microdosing for anxiety and depressive symptoms is a topic that balances between hype and science. As researchers, it is our duty to keep the two apart.

The current evidence is not sufficient to recommend microdosing as a treatment. It is sufficient to justify further research. And it is sufficient to say: there is something here that deserves our attention — but not our blind trust.

Microdosing is not a substitute for therapy. It is not a substitute for human connection, exercise, sleep, and all the other things that demonstrably support mental health. If it has a place, it is as a supplementary subject of research — not as a cure-all.

Take care of yourself. And if you need help, get it.